Advertisement
Advertisement
U.S. markets open in 16 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Celyad Oncology SA (CYAD)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
1.0300+0.0300 (+3.00%)
At close: 11:00AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.0000
Open0.9882
Bid0.9700 x 1000
Ask1.0700 x 1300
Day's Range0.9882 - 1.0300
52 Week Range0.9450 - 5.0970
Volume5,515
Avg. Volume5,163
Market Cap25.763M
Beta (5Y Monthly)0.94
PE Ratio (TTM)N/A
EPS (TTM)-1.5070
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.52
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYAD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Celyad Oncology SA
    Daily – Vickers Top Buyers & Sellers for 03/21/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Business Wire

    Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights

    MONT-SAINT-GUIBERT, Belgium, November 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the "Company"), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2022.

  • Business Wire

    Celyad Oncology Provides Strategic Update

    MONT-SAINT-GUIBERT, Belgium, October 12, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an update on its strategic business model, clinical trial programs, and the related operational and organizational steps and cost-saving measures that it will undertake.

  • Business Wire

    Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction

    GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium, September 20, 2022--Regulatory News: Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufa

Advertisement
Advertisement